Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Breast Neoplasms 20Carcinoma, Renal Cell 10Neuroendocrine Tumors 7Neoplasm Metastasis 7Recurrence 4Tuberous Sclerosis 3Triple Negative Breast Neoplasms 3Neoplasms 3Kidney Neoplasms 3Endometrial Neoplasms 3von Hippel-Lindau Disease 2Skin Neoplasms 2Sarcoma 2Meningioma 2Glioma 2Gastro-enteropancreatic neuroendocrine tumor 2Diffuse Intrinsic Pontine Glioma 2Carcinoma, Hepatocellular 2Adenoma, Islet Cell 2Waldenstrom Macroglobulinemia 1Vascular Malformations 1Unilateral Breast Neoplasms 1Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Diseases 1Thymus Neoplasms 1Seizures 1Sarcoma, Kaposi 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pheochromocytoma 1

Interventions

Rituximab 16zanubrutinib 12ibrutinib 9venetoclax 8Cyclophosphamide 8pirtobrutinib 5fludarabine phosphate 5Whole-Body Irradiation 5Sirolimus 5Mycophenolic Acid 5Bendamustine Hydrochloride 5acalabrutinib 4Peripheral Blood Stem Cell Transplantation 4Dexamethasone 4ixazomib 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Lenalidomide 3Cyclosporine 3Bortezomib 3Biopsy 3fludarabine 2carfilzomib 2Tacrolimus 2Prednisone 2Melphalan 2Etoposide 2Cyclosporins 2Calcium Dobesilate 2CT-P10 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Waldenstrom Macroglobulinemia × Everolimus × 1 year × Clear all
NCT07426484 2026-02-23

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Dana-Farber Cancer Institute

Phase 4 Not yet recruiting
80 enrolled
DermatologicLymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Waldenstrom Macroglobulinemia, Skin Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡